Athanor Capital, LP Ascendis Pharma A/S Transaction History

Athanor Capital, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$121.62 - $145.29 $1.19 Million - $1.42 Million	-9,779 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$124.92 - $173.33 $1.86 Million - $2.58 Million	-14,874 Reduced 60.33%	9,779 $1.26 Million
Q4 2020 Feb 16, 2021	BUY	$151.2 - $182.76 $1.36 Million - $1.64 Million	8,994 Added 57.44%	24,653 $4.11 Million
Q3 2020 Nov 16, 2020	SELL	$134.29 - $154.32 $1.52 Million - $1.75 Million	-11,350 Reduced 42.02%	15,659 $2.42 Million
Q2 2020 Aug 13, 2020	BUY	$110.87 - $156.01 $2.58 Million - $3.62 Million	23,231 Added 614.9%	27,009 $4 Million
Q1 2020 May 14, 2020	SELL	$97.01 - $145.11 $1.99 Million - $2.98 Million	-20,505 Reduced 84.44%	3,778 $425,000
Q4 2019 Feb 14, 2020	BUY	$91.45 - $139.12 $708,280 - $1.08 Million	7,745 Added 46.83%	24,283 $3.38 Million
Q3 2019 Nov 14, 2019	BUY	$95.8 - $118.9 $798,780 - $991,388	8,338 Added 101.68%	16,538 $1.59 Million
Q2 2019 Aug 13, 2019	BUY	$107.11 - $132.09 $674,793 - $832,167	6,300 Added 331.58%	8,200 $944,000
Q1 2019 May 13, 2019	BUY	$62.15 - $129.99 $118,085 - $246,981	1,900 New	1,900 $224,000

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Athanor Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Athanor Capital, LP with notifications on news.